Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis
18 December 2018 09:00 GMT Roxadustat approved in China for the treatment ofanaemia in chronic kidney disease patients on dialysis China is the first country to approve roxadustat AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has now received formal marketing authorisation from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and new oral treatment for patients with anaemia caused by chronic kidney disease (